Is Ultragenyx Pharmaceutical Inc (RARE) a Bad Choice in Biotechnology Tuesday?

A rating of 81 puts Ultragenyx Pharmaceutical Inc (RARE) near the top of the Biotechnology industry according to InvestorsObserver. Ultragenyx Pharmaceutical Inc's score of 81 means it scores higher than 81% of stocks in the industry. Ultragenyx Pharmaceutical Inc also received an overall rating of 68, putting it above 68% of all stocks. Biotechnology is ranked 18 out of the 148 industries.

RARE has an Overall Score of 68. Find out what this means to you and get the rest of the rankings on RARE!

See Full RARE Report

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. InvestorsObserver makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts. These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Ultragenyx Pharmaceutical Inc Stock Today?

Ultragenyx Pharmaceutical Inc (RARE) stock is lower by -2.12% while the S&P 500 has risen 0.73% as of 1:29 PM on Tuesday, Mar 12. RARE is lower by -$1.03 from the previous closing price of $48.51 on volume of 179,171 shares. Over the past year the S&P 500 has gained 33.71% while RARE has risen 16.14%. RARE lost -$8.25 per share the over the last 12 months. Click Here to get the full Stock Report for Ultragenyx Pharmaceutical Inc stock.